• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP-As measles cases mount, new report highlights safety of early vaccination for infants

Lance

MPH, CSP & CIT Retired, CHMM Emeritus

As measles cases mount, new report highlights safety of early vaccination for infants​

Laine Bergeson

Today at 11:57 a.m.
Measles


As Americans prepare for holiday travel amid a nationwide measles resurgence and diminished federal public health communications, a new paper from the Center for Infectious Disease Research and Policy’s (CIDRAP’s) Vaccine Integrity Project (VIP) at the University of Minnesota highlights data showing that infants as young as 6 months can safely receive the measles, mumps, and rubella (MMR) vaccine. CIDRAP is the publisher of CIDRAP News.

The United States has recorded more than 5,400 measles cases and 10 measles-related deaths across 45 states this year. Today, the Pan American Health Organization formally revoked the nation’s measles elimination status, which it has held for more than 26 years. Loss of measles elimination status signals that the virus has been spreading in one continuous chain for at least a year.

Routine MMR vaccination begins at 12 to 15 months, but for decades, federal health authorities and medical societies have recommended early measles vaccination, sometimes called a “zero dose,” for eligible infants ages 6 to 11 months who will be traveling internationally or living in or traveling to areas experiencing active measles outbreaks.

More families with young infants may find themselves traveling to areas where measles is circulating. In the past, that would have been something you would only expect to encounter in a low-income country.
Measles is particularly dangerous for infants, because the protective antibodies they receive from their mothers wane during their first months of life.

“There are several critical reasons why we're emphasizing these recommendations now. First and foremost, the risk of measles exposure in the United States has changed dramatically,” says CIDRAP Director Michael T. Osterholm, PhD, MPH. “And with the holiday travel season approaching, more families with young infants may find themselves traveling to areas where measles is circulating. In the past, that would have been something you would only expect to encounter in a low-income country.”

Zero dose does not replace 2 routine doses​

The VIP data assessment found that the zero dose provides meaningful protection for infants, without evidence of an increased risk of adverse events, compared with vaccination at older ages. Specifically, the data show that MMR vaccine effectiveness is 58% when given before 9 months and 83% effective when given from 9 to 11 months.

The assessment also highlights a randomized clinical trial involving 6,540 Danish infants that found that MMR vaccination at 5 to 7 months was not linked to higher rates of adverse reactions compared with placebo. A separate review that included 15 safety studies found no difference in the risk of adverse events between those vaccinated before nine months and those vaccinated at older ages.

But, notes the paper, the immune response to vaccination before 12 months may be less durable than later vaccination, so infants who receive a zero dose should still get the recommended two-dose MMR series beginning at 12 to 15 months.

Parents should be aware of some expected reactions to the MMR vaccine. “We do know the vaccine can cause a fever in children, and as with any intervention that can cause a fever, it has been associated with febrile seizures in some children,” says CIDRAP clinical adviser and paper coauthor Heidi Moline, MD, MPH.

“However, this risk is very low, and in our review we found no data to suggest this risk was higher in infants six to 11 months than in older children,” she adds. “Overall, the MMR vaccine is safe and highly effective at preventing severe disease and complications from the measles virus.”

Clear, evidence-based information needed​

In the past, federal health agencies have played a central role in communicating disease risks and vaccine guidance, but the Centers for Disease Control and Prevention (CDC) has been mostly silent during the largest measles outbreak in decades.

For example, the CDC’s X (formerly Twitter) account hasn’t posted outbreak-related information since August, when it amplified a dispute between Pennsylvania and Department of Health and Human Services Secretary Robert F. Kennedy Jr. over the number of measles-related deaths. The state has now reported seven measles related deaths.

“The failure to communicate clearly and consistently sends a signal that the issue is not important,” says Osterholm, adding that people are less likely to educate themselves about issues perceived as unimportant.

The early dose isn't new, and the evidence supports its safety and effectiveness. What's changed is the urgency of making sure families know about it.
“Parents and healthcare providers need clear, evidence-based information about how to protect infants who are too young for their first routine MMR dose,” says CIDRAP Director of Media Relations and Public Affairs and paper coauthor Kevin Griffis. “The early dose isn't new, and the evidence supports its safety and effectiveness. What's changed is the urgency of making sure families know about it.”

This is especially true as families gear up to travel this holiday season. “Measles is one of the most infectious viruses we know of—it spreads easily when an infected person breathes, coughs or sneezes,” says Moline. “As we travel and gather for the holidays, parents of infants are encouraged to talk to their child's health provider to see if a zero dose makes sense.”

 
Back
Top Bottom